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= A b s t r ac t = Recently, 'ln-antimyosin monoclonal antibidies (l ' 'ln-AMAb) have 
been introduced for the diagnosis of myocardial infarction. The purpose of this 
study was to investigate the feasibility of using this agent for the early detection 
of cardiac damage induced by doxorubicin. The degree of drug induced change in 
99m the myocardium was evaluated histologically. Tc pyrophosphate (99m~c-~YP) ,  
known to preferentially accumulate in Adriamycin caused lesions, was used as  a 
control radiopharmaceutical. Myocardial uptake of 'ln-AMA~ and 9 9 m ~ c - ~ ~ ~  
was measured in 1 2  controls and 10 Adriamycin treated rabbits. The results 
indicated the following: 1) 'llln-AMAb uptake in the heart correlated well with 
the degree of pathology (r=0.95); 2) 9 9 m ~ c - ~ Y P  uptake was also correlated with 
cardiac damage (r=0.77); 3) The uptake ratio (expressed as percent injected dose 
per gram myocardial tissue) of Adriamycin treated animals vs. controls was 2.7:l 
11 1 for In-AMAb and 9.2 for 99mTc-PYP nt 2 4  and 2 hours after intravenous 
99m injection, respectively; 4) considerable non-specific Tc-PW accumulation was 
measured in the lungs and kidneys and was significantly higher in drug treated 
11 1 animals compared to  controls. In-AMAb accumulation remained unchanged in 
these organs. We conclude that ll'ln-AMA~ accurately detects cardiac toxicity 
induced by Adriamycin but that 9 9 m ~ c - ~ Y P  still remains an acceptable agent in 
part because, of its availability and higher tracer concentration in the cardiac 
lesions. 
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l NTRODUCT l ON 
Received March 1993, and in final form June 1993. Adriamycin (Doxorubicin hydrochloride), an 
t Supported by Grant N O  02-91-177 from the Seoul National University anthracycline antibiotic, is a highly effective and 
Hospital Research Fund commonly used chemotherapeutic agent. ~184qz q44q qqqz9: o]g%,  3571, 
o]+++, iL%$ However, it can cause a severe and fatal form of 
delayed irreversible cardiotoxicity. There is no 
reliable method to predict clinically significant 
cardiac toxicity and the pathogenic mechanism 
of Adriamycin induced cardiomyopathy has not 
been elucidated. Some investigators have 
uti l ized left ventricular ejection fraction to 
determine cardiotoxicity but the method is 
insensitive because myocardial damage must 
already be extensively present to depress global 
function for definite detection. 
Infarct-avid radiopharmaceuticals such as 
99n'~c-pyrophosphate (PYP) and a newly 
developed agent, radiolabeled antimyosin 
antibody (AMAb) have been shown to be useful 
for the detection of myocardial injury and are 
used commonly in the diagnosis of acute 
myocardial infarction (Khaw et a/. 1976; Khaw et 
a/. 1978; Parkley et a/. 1974; Botvinick et a/. 
1975; Khaw et a/. 1980; Beller et a/. 1977;Lee et 
a/. 1991). 
The purpose of this investigation was to 
determine the accumulation of "'ln-antimyosin 
monoclonal antibody in rabbit myocardium with 
experimentally induced cardiac damage caused 
by the intravenous administration of Adriamycin 
at doses previously felt to be subtoxic and to 
compare these results with those of g g m ~ c -  
pyrophosphate accumulation and histologic 
findings in the same animal. 
MATER l ALS AND METHODS 
The monoclonal antimyosin antibody used in 
this study was a Fab fragment of IgG derived 
from BALBIc mice (R l lD lO ) ,  having specific 
affinity to human cardiac myosin. Two mCi of 
11 1 In-C13 were added to an aliquot of 0.5mg of 
DTPA-R1 ID10 Fab in 0.1 M citrate buffer (pH 5. 
0). The reaction mixture was gently mixed at 
room temperature for 10 minutes. Before 
administration the labeled antibody was filtered 
through 0.22 um micropore protein binding filter 
11 1 (Gelem). The average In binding efficiency, 
measured by  Sephadex column chromato- 
graphy was 90%. 
This study was performed in twenty-two 
mature New Zealand White rabbits weighing 
between 8 to 10 pounds. Ten drug treated and 
12 control rabbits were used. The treated group 
of animals received 2.5 mglkg Adriamycin by 
intravenous injection once each week for 4 
weeks via the marginal ear vein while the control 
group received the same volume of 0.9% saline 
solution. Adriamycin was freshly prepared before 
each injection. 
All animals were injected with 40-50 uCi of 
11 1 In-antimyosin antibody at 24 hours before 
scheduled sacrifice and 200-250 pCi of ""Tc- 
pyrophosphate at 2 hours before sacrifice. At the 
end of the experiment, the rabbi ts  were 
sacrificed by intravenous injection of 120mg of 
pentobarbitol. The heart was divided into left 
ventricle, right ventricle, septum and atrial 
portions and multiple transmural myocardial 
specimens were obtained. Weighed sections of 
each organ were counted in a well scintillation 
counter along with appropriate standards. The 
percentage of injected doselgm tissue was 
calculated. Slices of myocardium and kidney 
were f ixed in buffered neutral formalin, 
embedded in paraffin, and tissue sections were 
stained with Masson's tr ichrome and 
hematoxyline-eosin. The stained sections were 
examined by light microscopy and assigned a 
histologic score without knowledge of treatment 
category by an expert in cardiac pathology. The 
following scoring system of the myopathic 
change adopted from Bristow et a1 (Bristow et a/. 
1981; Bristow et a/.  1980) was used: Grade 
O=normal myocardium, no Adriamycin effect; 
Grade I=occasional sparse numbers of foci of 
vacuolated myocytes and/or minimal interstitial 
fibrosis; Grade Il=moderate number of focal 
myocytes showing vacuolization and/or myofibril 
loss; Grade I l l=many generalized affected 
myocytes showing vacuolization and diffuse 
interstitial fibrosis. 
Statist ical analysis of the data was 
performed using unpaired Student's t test and 
Spearman's rank correlation coefficient test for 
nonparametric data (Snedecor and Cochran 
1 976). 
RESULTS 
The biodistribution of ' " ln-AMA~, in control 
and Adriamycin-treated groups, expressed as % 
injected doselgram tissue(%lDlgm) at 24 hours 
after injection for the heart and each organ, is 
shown in Table 1. The mean cardiac uptake of 
11 1 In-AMAb was 0.021 in the control group and 
0.056 in the Adriamycin-treated group. The 
difference between the two groups was 
signif icant(p<0.005). The ratio of antibody 
accumulation of Adriamycin-treated over control 
rabbit based on the %ID/gm cardiac tissue was 
about 2.7:1. However, for other organs (lungs, 
kidneys, liver, spleen and bone) there was little 
difference between the two groups. Figure 1 
presents the distribution of individual data of 
%ID/gm in each port ion of the heart(left 
ventricle, right ventricle, septum and atrium). In 
all samples there was a significant increase of 
' " l n -AMA~  accumulation in the Adriamycin- 
treated group compared with controls. Six of 10 
rabbits treated with subtoxic doses of 
Adriamycin developed damaged hearts and had 
increased cardiac " ' ln-AMA~ activity which was 
greater than two standard deviations from the 
mean of control animals. 
Table 2 and Figure 2 demonstrate the results 
of the biodistribution of 99mTc-pyrophosphate in 
control versus Adriamycin-treated treated 
animals in terms of %ID/gm tissue. Mean values 
of 9 9 m T c - ~ ~ ~  uptake in the heart were 0.006 and 
0.055 respectively (p<0.05). The distribution of 
individual data of %ID/gm tissue in each 
specimen of the heart revealed that 8 of 10 
rabbits had an accumulation greater than 2 SD 
of the mean control value. In addition, the kidney 
and lung also showed significantly higher 
pyrophosphate uptake in Adriamycin-treated 
animals. The higher percent uptake of 99mTc-PYP 
in the kidney and lung may correlate with 
Adriamycin induced renal toxicity and 
congestive heart failure, respectively. 
The histologic changes in the hearts of 15 
Adriamycin treated animals were correlated with 
biodistribution results. As shown in Figures 3 and 
4, qualitatively similar findings were observed in 
these rabbits. There was a strong relationship 
between both ' " ln -~MAb and 99mTc-PYP uptake 
and the severity of myocardial damage by 
microscopic examinations. By Spearman's rank 
correlation coefficient (r) between " ' l n -AMA~ 
and histologic grading was 0.95 which was 
statistically significant (p<0.001) and better than 
the r value between 9 9 m ~ c - ~ ~ ~  and histologic 
grading which was 0.77 with a statistical 
significance of p<0.005. 
Interestingly, there were two rabbits in the 
Table 1. Biodistribution of lllln-antimyosin antibody in control and adriamycin-treated groups (Mean + 1 SEM) 
-. - - .  -- 
% Doselg tissue at 2 hrs after injection 
Organ 
Control (n= 12) Adriamycin (n= 10) 
-- - - . - 
Heart 0.021 + 0.002 0.056 + 0.010 
Left Ventricle 0.020 + 0.002 0.063 + 0.010 
Right Ventricle 0.022 + 0.003 0.052 + 0.01 1
Septum 0.021 + 0.002 0.062 + 0.012 
Atrium 0.023 + 0.002 0.050 + 0.009 
Lungs 0.028 + 0.002 0.033 k 0.003 
Kidneys 0.635 + 0.069 0.697 + 0.1 14 
Liver 0.106 + 0.005 0.121 + 0.01 1
Spleen 0.1 15 & 0.008 0.123 + 0.017 
Rib 0.034 + 0.007 0.027 + 0.007 
- -. - .  -- - ~ -. -- -  -. . - - -. - - 
NS; not significant 
p value 
0 Control 
Fig. 1. Distribution of " ' ln -AMA~ (ID%/grn) in each 
portion of the heart. 
Adriamycin treated group which showed normal 
PYP accumulat ion despite the abnormal 
histology and one rabbit that showed mild "'ln- 
AMAb uptake despite normal histology. 
D l  SCUSS l ON 
Doxocubicin hydrochloride (Adriamycin) 
has been clearly shown to be one of the most 
effective antitumor drugs in cancer 
chemotherapy (Bulum and Carter 1975; 
Benjamin et a/. 1974). Its efficacy appears to 
depend on high cumulative dosages. However, 
the major dose-limiting side effect which is 
unique for this antibiotic is the development of 
dose related cardiotoxici ty(doxorubicin 
cardiomyopathy) (Lefrak et a/. 1973; Rinehart et 
a/. 1974). The risk of heart failure has been 
reported to be negligible at total doses of less 
than 500 mgIm2 (0.27%), but is much more likely 
to occur at doses above that level. The 
incidence of symptomatic congestive heart 
failure is approximately 10% of patients who 
received 550 to 660mglm2 and 35% of patients 
who received larger doses (more than 
650mglm2) (Bristow 1982). Up to 50% of patients 
developing Adriamycin related congestive heart 
failure die of cardiac causes (Lefrak et a/. 1975; 
Cortes et a / .  1975). Jaenke (Jaenke 1976; 
Jaenke 1974) has descr ibed a similar 
myocardial syndrome from Adriamycin produced 
experime tally in rabbits. Gorton (Gorton et a/. 
1980) treated rabbits effectively with a dose of 
14.4 mglkg (158 mg/m2), a level analogous to 
the 550 mgIm2 described as the typically safe 
human dose. 
The recognition of the earliest preclinical 
stages of doxorubicin induced cardiotoxicity 
must remain a goal for all physicians using this 
drug. So far, there is no reliable prediction of 
cl inical ly signif icant doxorubicin induced 
cardiotoxici ty.  The morphologic changes 
observed in doxorubicin induced cardiotoxicity 
consist of: 1) cardiac dilatation and mural 
thrombosis; 2) degeneration and atrophy of 
cardiac muscle cells and 3 )  interstitial edema 
and fibrosis (Fervans 1978). The degeneration of 
myocardial cells can be  characterized by  
myofibrillar loss and cytoplasmic vacuolization. 
As shown in this study, one striking finding is the 
wide range of histologic change and myocardial 
antimyosin antibody accumulation in the sub- 
toxic dose of Adriamycin-treated animals, 
suggesting differing individual sensitivity to 
Adriamycin. In fifteen animals examined by 
microscopy, six rabbits had developed mild 
myocardial lesions (Grade I), two moderate 
(Grade II) and only one severe (Grade Ill) at a 
total Adriamycin dose of 10 mglkg. Recently 
cardiac imaging using radionuclide labeled 
compounds has proven useful for the detection 
Table 2. Blod~strlbutlon of 99mTc-pyrophosphate (PYP) In control and adriamyc~n-treated groups 
(Mean + 1 SEM) 
- -- -- -- - - -- - -- -- -. - 
Organ 











% Doselg tissue at 2 hrs after injection 
- -- p value 
Control (n= 12) Adriamycin ( n =  10) 
.- - -- ~ 
0.006 + 0.0003 0.055 + 0.022 <0.05 
0.006 * 0.0002 0.068 * 0.027 <0.05 
0.007 * 0.0004 0.078 + 0.037 <0.05 
0.007 + 0.0003 0.046 * 0.018 <0.05 
0.008 * 0.0004 0.039 + 0.012 <0.01 
0.010 + 0.001 0.016 + 0.002 <0.005 
0.209 * 0.018 0.487 * 0.078 <0.005 
0.008 * 0,001 0.014 * 0.004 NS 
0.008 * 0,001 0.014 * 0.004 NS 
0.074 + 0.018 0.041 + 0.009 NS 
. -- 
NS; not significant 
0 Control "'ln -AMAb 
Tc-99m-PY P Adriamycin 
LV  RV Septum Atrium 
Fig. 2. Distribution of 9 9 m ~ c - ~ ~ ~  (ID%/gm) in each 
portion of the heart. F i g. 3. Correlation between the histologic changes 
and biodistribution results (ID%/gm) of "'ln- 
AMAb. 
of myocardial injury. Localization and sizing of 
acute myocardial infarcts have been done a/. 1973), 99mTc-glucoheptonate (Rossman et a/. 
successfully with 99m~c-tetracycline (Holman et 1975) and 99m~c-pyrophosphate (Parkley ef a/. 
e 0.00 
I I1 III Grade 
F i g. 4. Correlation between the histologic changes 
and biodistribution results (ID%lgm) of ""'Tc- 
pyrophosphate 
1974; Coleman et a/. 1976). Although the exact 
mechanism of accumulation of 9 9 m ~ c - ~ ~ ~  has 
not been completely defined, it appears to be 
due in part to the PYP's binding to intracellular 
components v ia injured myocardia l  cel l  
membrane allowing PYP to accumulate in the 
form of hydroxyapati te- l ike crystals in 
mitrochondria. This is often associated with cell 
necrosis and intracellular calcium accumulation 
(Buja et a/. 1977). Some investigators (Gorton et 
a/. 1980; Chacko et a/. 1977) have reported that 
myocardial scanning using """Tc-PYP may 
prove to be  a valuable diagnost ic tool in 
monitor ing the adverse effects of the 
Adr iamycin.  They were able to detect  
myocardia l  damage before its c l in ical  
appearance. In our study g g m ~ c - ~ ~ ~  increasingly 
accumulated in hearts with Grade 0-111 
pathology, indicating that this agent can be 
utilized in staging Adriamycin cardiotoxicity. 
More recently Khaw and others (Khaw et a/. 
1976; Khaw et a/. 1978; Khaw et a/. 1980; Beller 
et a/. 1977; LaFrance et a/. 1985; Takeda et a/. 
1985) localized myocardial infarcts by using 
radiolabeled antibodies to cardiac myosin. After 
intravenous injection of radioiodine-labeled 
fragments of antibodies that are specific for 
cardiac myosin, ratios of up to 6:1 between 
infarcted and normal myocardium were found in 
animal models. This ratio increased to greater 
than 20: 1 in reperfused myocardial infarctions. 
Early studies (Khaw et a/. 1978) used (Fab1)2 
while more recent studies used a Fab fragment 
antibody. With both, (Fab1)2 and Fab, there was 
an inverse relationship between regional 
myocardial blood flow and uptake of the tracer. 
1 1  1 Similar results usicg In-AMAb have been 
previously reported by our group and other 
investigators(LaFrance et a/. 1985; Chacko et a/. 
1977). 
In this study we measured the distribution of 
1 1 1  In-antimyosin monoclonal ant ibody in 
myocardium of control rabbits and of animals 
treated with Adriamycin and we compared these 
results with those of ggm~c-pyrophosphate  
accumulation and correlated these results with 
radiopharmaceutical accumulation histologic 
findings in the same animals. Whether the ratio 
of ' l ' l n - ~ ~ ~ b  accumulation between Adriamycin 
treated and control rabbits in this study at 24 
hours after intravenous injection was due only to 
lack of specificity of the antibody or was due to 
other factors was not studied. 
The specif ic i ty of the human R1 1 D l 0  
antibody towards rabbit tissue also has not been 
previously evaluated. Investigations in dogs, 
however, have shown that the affinity of this 
antibody towards infarcted dog heart was similar 
to that of humans (Khaw et a/. 1976). 
The use of control rabbi ts  a long with 
histological and PYP comparison of our data 
revealed that there is some cross reactivity of the 
rabbit myosin with R1 ID10  murine antibody 
d i rected against human myosin. Since 
considerable similarities in mammalian myosin 
structure exist, cross reactivity was unexpected. 
Based upon our canine infarction work(LaFrance 
e t a / .  1985), the ratio of " ' l n - ~ ~ ~ b  accumulation 
in human myocardium damaged by Adriamycin 
may be similar to those higher ratios since better 
specificity of R 1 1 D l  0 AMAb exists for human 
myosin as compared to rabbit myosin. 
1 1 1  Whether In-AMAb levels in Adriamycin 
damaged myocardium resulting in myocardial 
necrosis will be greater in humans requires 
further study. 
Using this experimentally induced rabbit 
model and lllln-antimyosin antibody, we were 
able to detect increased myocardial uptake 
before cl inical  appearance.  Statistically 
signif icant increased accumulat ion of 
radioact iv i ty occurred even though these 
animals had been treated with what had 
previously been described as a sub-toxic 
dosage of Adriamycin (1  Omglkg), levels 
previously expected to cause no cardiotoxicity. 
The significant correlation between the 'l ' ln- 
AMAb in the myocardium will occur at the stage 
when the damage is still at the cellular level 
rather than at the global organ level and it may 
prove to be a valuable tool in monitoring the 
adverse effects of the anthracycline antibiotics in 
patients. 
In conclusion, this study has demonstrated 
that(Khaw et a/. 1976) '11 l n - A M A ~  accumulation 
in the heart correlated better than PYP with the 
degree of pathology (r=0.95); (Khaw et a/. 1978) 
"""Tc-PYP uptake was also dependent on degree 
of cardiac damage (r=0.77); and (Parkley et a/. 
1974) however, the more favorable ratio of 
%ID/gm in the myocardium of treated animals 
occurred for g g m ~ c - ~ ~ ~  than for " ' l n - ~ ~ ~ b  to 
detect Adriamycin induced cardiac damage 
before the end stage o f  cardiac toxicity 
develops. This study supports the need for a 
similar study in humans to determine the relative 
advantages of " l l n - A M A ~ ,  g g m ~ c - ~ ~ ~  and 
histology. 
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